Introduction {#Sec1}
============

Acute respiratory distress syndrome (ARDS) is characterized by damage to the lung parenchyma, caused by either indirect or direct insults, including ventilation itself \[[@CR1]\]. Tidal hyperinflation and cyclic alveolar recruitment/derecruitment during mechanical ventilation can lead to an entity called ventilator induced lung injury (VILI) \[[@CR2], [@CR3]\]. A multi-centered clinical trial demonstrated that a lung protective strategy with tidal volumes (*V*~T~'s) of 6 ml/kg predicted body weight (PBW), and plateau pressures ≤30 cmH~2~O decreased mortality by a relative 22 % compared to control \[[@CR4]\]. A post hoc analysis of this study \[[@CR5]\] found that the lower the plateau pressure (*P*~plat~), the better the patient's chances of survival, even for *P*~plat~ substantially \<30 cmH~2~O, and these data suggested that even lower tidal volumes might further improve survival. Grasso and colleagues \[[@CR6]\] demonstrated that many ARDS patients ventilated using the ARDSNet strategy with table-based PEEP have a stress index indicating alveolar hyperinflation.

These data would suggest the use of even lower tidal volumes, but in severe ARDS the implementation of such a strategy may be limited by a therapeutic dilemma due to the increased likelihood of more severe hypercapnia and acidosis. The impact of hypercapnia on lung injury or on systemic effects including remote organ damage (myocardial insufficiency, renal failure, and hepatic/intestinal ischemia) is somewhat controversial \[[@CR7], [@CR8]\], delaying or preventing the implementation of adequate lung-protective strategies \[[@CR9]\].

In the last few years, extracorporeal, pumpless arterio-venous approaches to CO~2~ removal using an artificial membrane lung have been developed and tested for clinical use retrospectively in 90 patients \[[@CR10]\] demonstrating marked carbon dioxide removal and moderate oxygenation improvement. Additionally, in a prospective cohort study Terragni and coworkers \[[@CR11]\] used a CO~2~ removal device to reduce tidal volume lower than 6 ml/kg and observed an improvement of morphological markers of lung protection. However, their study was not a randomized clinical trial and there was no concurrent control group. We set out to investigate the effects of combining a very low *V*~T~ (3 ml/kg PBW) with arterio-venous extracorporeal CO~2~-elimination (avECCO~2~-R) in patients suffering from established ARDS.

We hypothesized mechanical ventilation using lower tidal volumes (3 ml/kg) assisted by avECCO~2~-R would enhance lung protection and hence increase 28-day and 60-day ventilator-free days, compared with mechanical ventilation using conventional tidal volumes (6 ml/kg).

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study was approved by the ethics committee of the Regensburg University Hospital (reference 07/012), and the ethics committees of all involved study centers. Before enrolment, written informed consent was obtained from the legal proxy of each patient. Patients were enrolled from September 2007 through December 2010 at eight intensive care units (ICU) in Germany and two ICU's in Austria.

Entry criteria were: (1) presence of ARDS according to the American-European Consensus Conference \[[@CR12]\] defined by bilateral infiltrates on chest X-ray, and a PaO~2~/FIO~2~ \<200 present for at least 2 h. At the time of screening patients could not have any evidence of left ventricular failure; (2) age ≥18 years; (3) history of mechanical ventilation \<7 days); (4) plateau pressure \>25 cmH~2~O at defined ventilator settings (PEEP/FIO~2~-table + *V*~T~ = 6 ml/kg); (5) absence of severe hemodynamic instability with high demand for vasopressors (mean arterial pressure ≥70 mmHg with continuous norepinephrine infusion ≤0.4 μg/kg/min). Exclusion criteria were: decompensated heart insufficiency, acute coronary syndrome, severe chronic obstructive pulmonary disease, advanced malignancy with life expectancy \<6 months, chronic dialysis treatment, lung transplant patients, proven heparin-induced thrombocytopenia (HIT), morbid obesity (body mass index \>40 kg/m^2^), cirrhosis of the liver Child Class ≥B (Child--Pugh scores ≥7), or acute fulminant hepatic failure, severe peripheral arterial occlusive disease, absence of limb doppler pulse, and acute brain injury (Glasgow Coma Scale ≤9).

To identify patients presenting with established ARDS and to help further rule out patients with acute cardiogenic pulmonary edema, the screening was followed by a stabilization period for 24 h, characterized by lung protective mechanical ventilation with high PEEP (≥12 cmH~2~O), the use of supportive measures, and hemodynamic evaluation (echocardiography). Patients who had ARDS criteria (PaO~2~/FIO~2~ \<200) after 24 h despite optimal supportive treatment were identified as those with established ARDS \[[@CR13]\], and were randomized through phone hot line by a random number table generated by the involved statistician with respect to the stratum pulmonary/non-pulmonary ARDS (Fig. [1](#Fig1){ref-type="fig"}). The principal investigator (TB) performed visits aimed at information and supervision of the study protocol in the participating centers. An independent Data Safety Monitoring Board monitored the study.Fig. 1Screening, randomization and follow-up according to study protocol. *V*~*T*~ tidal volume, *CVP* central venous pressure, *MAP* mean arterial pressure, *vvECMO* veno-venous ECMO

Treatment of the study group {#Sec4}
----------------------------

The intensive care management in both groups followed the 'best clinical evidence' recommended by the European Society of Intensive Care Medicine \[[@CR14]\]. The daily monitoring included the assessment of awakeness/sedation (Richmond Agitation Sedation Scale \[RASS\]) and the daily evaluation of the Sequential Organ Failure Assessment (SOFA) and the Simplified Acute Physiology Score (SAPS-II).

After randomization to the treatment group, percutaneous cannulation and initiation of pumpless extracorporeal lung assist (iLA AV, Novalung, Heilbronn, Germany) was performed. Unlike "classic" pump-driven extracorporeal carbon dioxide removal, iLA does not require a blood pump, because the extremely low resistance of this circuit allows flows of about 1--2 l/min with normal arterial pressures (for more detailed description: \[[@CR10], [@CR15]\]). Evaluation, cannulation and clinical monitoring for avECCO~2~-R can be found in electronic supplementary material (ESM).

After initiation of avECCO~2~-R, adaptation of the ventilation strategy according to study protocol was performed as follows: a rapid titration down to *V*~T~ 3 ml/kg/PBW, PEEP following ARDSNet "high-PEEP/FIO~2~" table \[[@CR16]\], respiratory rate 10--25/min with an inspiratory/expiratory ratio of 1:1. Termination of the avECCO~2~-R therapy and decannulation was performed according to a defined algorithm (see ESM).

Treatment of the control group {#Sec5}
------------------------------

The ventilatory management followed the algorithm of the study group except for the use of a *V*~T~ = 6 ml/kg/PBW. The target blood gases for both groups were: PaO~2~ ≥60 mmHg and arterial pH ≥7.2. The use of buffering (tris-(hydroxymethyl) aminomethane \[TRIS\]) was permitted if the patient had hypercapnia and respiratory acidosis (pH \<7.2).

Weaning and extubation procedures {#Sec6}
---------------------------------

In both groups daily screening was performed as a precondition for carrying out a spontaneous breathing trial (SBT): ability to breathe spontaneously (FIO~2~ ≤0.4, SaO~2~ ≥90 %, PEEP ≤8 cmH~2~O, hemodynamic stability, RASS score ≥−1, body temperature \<38.5°).

SBT was carried out over 1 h with augmented spontaneous breathing (ASB) 5 cmH~2~O with an active humidifier or, 10 cmH~2~O with HME filter (PEEP ≤8 cmH~2~O, flow trigger \<3 l/min). Patients were extubated when no deterioration was observed over a 1 h period.

Data collection {#Sec7}
---------------

At the time of screening (24 h prior to randomization) physiologic data were recorded and relevant laboratory, radiographic and clinical findings were collected. Throughout the complete study period, data on ventilator settings, laboratory, physiologic, radiographic and interventional data were recorded. Relevant data of the ventilation management (*V*~T~, PEEP, *P*~plat~, minute ventilation, proportion of spontaneous ventilation on minute ventilation, arterial oxygen saturation) as well as results of the blood gas analyses (PaO~2~, PaCO~2~, pH) were recorded three times daily (8 a.m., 2 p.m., 10 p.m.) and the mean values of repeated measures were used for further analysis. SOFA score, SAPS-II and RASS scores were calculated daily (8 a.m.).

In addition, in a subgroup of study patients of the Regensburg University Hospital, depending on 'in-the-daytime'-availability of requested lab values, the levels of proinflammatory cytokines (tumour necrosis factor \[TNF\], interleukin 6 \[IL-6\] and interleukin 8 \[IL-8\]) were assessed from serum probes of avECCO~2~-R-patients (*n* = 20) and control patients (*n* = 15) at various time points during the study, since the measurement of these parameters is part of the routine laboratory program in this hospital. Furthermore, in all participating centers the daily cumulative doses of vasopressors (norepinephrine, adrenaline, dobutamine), sedative and analgesic agents (sufentanil, propofol, midazolam) and net fluid balances were calculated in each patient and recorded.

Primary outcome {#Sec8}
---------------

The primary outcome parameter was the proportion of days without assisted ventilation in a 28-day period ("ventilator-free" days within 28 days \[28-VFD\]) and in a 60 days period ("ventilator-free" days within 60 days \[60-VFD\]) \[[@CR17]\].

Secondary outcomes {#Sec9}
------------------

Secondary outcomes were: inspiratory plateau pressure levels (*P*~plat~), the proportion of spontaneous breathing as a percentage of the minute ventilation (automatically calculated by the ventilator's software), the RASS score, hemodynamic changes, the incidence of complications or adverse reactions, the frequency and duration of other adjunctive therapeutic measures, transfusion requirements \[packed red blood cell transfusions (units), fresh frozen plasma units, platelet transfusion\], the daily cumulative doses of analgesic and sedative agents, cumulative catecholamine requirements/24 h throughout the study period, frequency and duration of renal replacement therapy, the number of failing organs, the "organ-failure-free days" within 28 days after randomisation, and "in-hospital" mortality.

Statistical analysis {#Sec10}
--------------------

Assuming an increase in 28-VFD from 6.0 ± 10 (control group) to 11.0 ± 8 (study group \[[@CR13]\]), we estimated that 53 patients would be needed per group for a power of 0.8 and an alpha of 0.05 (calculation by Charitè Centrum für Therapieforschung, Berlin, Germany). We assumed a "drop-out-rate" of 10 % and we calculated that 120 patients would need to be enrolled. However, after an interim analysis with 56 patients by the Data Safety Monitoring Board, it was decided to limit the study period to 3 years, since a statistical significant difference was not expected in a longer study period.

We used a Student's *t*-test, the Wilcoxon test, the chi-square test or Fisher's exact test to assess differences between the groups, as appropriate. A Kaplan--Meier curve was calculated and plotted to assess the days until successful weaning from the ventilator. Furthermore, a nonparametric analysis of longitudinal data in factorial experiments was performed. Changes in interesting clinical outcomes with respect to time were analyzed using multivariate nonparametric analysis of longitudinal data in a two-factorial design (1st \[independent\] factor: groups, 2nd \[dependent\] factor: repetitions in time). Therefore, all the time points were simultaneously compared on the corresponding response curves (analysis according to Brunner \[Brunner-analysis [@CR18]\]). Additionally, a post hoc analysis was performed in patients with greater hypoxemia (PaO~2~/FIO~2~ ≤150) regarding primary outcome parameters. The reported *P* values are two-sided and significance was set at *P* \< 0.05.

Results {#Sec11}
=======

Between September 2007 and December 2010, 40 patients were randomized to avECCO~2~-R and 39 patients to control. Baseline data are given in Table [1](#Tab1){ref-type="table"}. Patients did not differ with respect to age and body mass index, but in the avECCO~2~-R-group there were more patients with secondary ARDS. Ventilatory and gas exchange data are shown in Table [2](#Tab2){ref-type="table"}.Table 1Baseline characteristics of the patientsavECCO~2~-R (*n* = 40)Control (*n* = 39)Age (years)49.8 ± 1248.7 ± 17Gender (male/female)38/230/9Lung Injury Score (Murray)2.8 ± 0.72.7 ± 0.8Body mass index (kg/m^2^)28.6 ± 528.8 ± 5Source of ARDS Pulmonary/non-pulmonary ARDS31/937/2*Non*-*pulmonary*SIRS/Sepsis51Massive transfusion10Trauma31*Pulmonary*Pneumonia24 (58 % bacterial)21 (62 % bacterial)Aspiration16Lung contusion69Inhalation10Comorbidities Diabetes mellitus23 COPD53 Arterial hypertension107 Coronary artery disease11 Chronic renal impairment20 Other1915  Atrial fibrillation32  Alcohol use disorder23  Obesity23The data are presented as mean ± standard deviation or absolute numbersTable 2Ventilation parameters and gas exchange after 24-h stabilization period at randomizationavECCO~2~-R (*n* = 40)Control (*n* = 39)*p*PaO~2~/FIO~2~152 ± 37168 ± 370.044PaCO~2~ (mmHg)57.3 ± 1254.3 ± 90.352Arterial pH7.34 ± 0.077.36 ± 0.070.317*V*~T~ (ml/kg, PBW)5.9 ± 1.26.0 ± 0.60.495Minute ventilation (l/min)9.9 ± 1.69.8 ± 2.40.745Frequency/min22.4 ± 322.7 ± 3.50.854PEEP (cmH~2~O)16.1 ± 316.0 ± 30.898Plateau pressure (cmH~2~O)29.0 ± 528.0 ± 70.384Delta (PEEP-Plateau) (cmH~2~O)12.9 ± 412.4 ± 40.475FIO~2~0.62 ± 0.20.53 ± 0.10.028The data are presented as mean ± standard deviation

Initially all patients were ventilated with high PEEP and low tidal volume according to the ARDSNet protocol, and had moderate hypercapnia. At randomization there were no significant differences regarding mean arterial pressure, heart rate or demand vasopressor uses (data not shown). However, there was a significantly lower PaO~2~/FIO~2~-ratio in the intervention arm. The mean duration of iLA-treatment was 7.4 ± 4 days with a mean blood flow of 1.3 ± 0.2 l/min throughout the treatment period.

Primary outcome results {#Sec12}
-----------------------

We found no statistical differences in VFD-28 or VFD-60 between groups, (Table [3](#Tab3){ref-type="table"}), but a post hoc analysis demonstrated that surviving patients with greater hypoxemia (PaO~2~/FIO~2~ ≤150 at randomization) treated with avECCO~2~-R had a significantly shorter period of ventilation (VFD-60 = 40.9 ± 12.8) compared to control (28.2 ± 16.4, *p* = 0.033) Fig. [2](#Fig2){ref-type="fig"}). Non-pulmonary organ failure free days within 60 days, intensive care and hospital days were not statistically different between groups.Table 3Outcome parameters of the studyAll patientsSubgroup: PaO~2~/FIO~2~ \<150avECCO~2~-RControl*p*avECCO~2~-RControl*p*Ventilator-free-days-2810.0 ± 89.3 ± 90.77911.3 ± 7.55.0 ± 6.30.033Ventilator-free-days-6033.2 ± 2029.2 ± 210.46940.9 ± 12.828.2 ± 16.40.033Non-pulmonary organ failure free days-6021.0 ± 1423.9 ± 150.44724.1 ± 7.529.0 ± 17.70.428Lung injury score on day 102.2 ± 0.62.1 ± 0.50.8542.3 ± 0.82.2 ± 0.50.601Length of stay in hospital (days)46.7 ± 3335.1 ± 170.11342.0 ± 16.640.3 ± 15.70.815Length of stay in ICU (days)31.3 ± 2322.9 ± 110.14425.9 ± 13.131.0 ± 12.70.258In-hospital mortality7/40 (17.5 %)6/39 (15.4 %)1.0001/21 (4.8 %)1/10 (10 %)0.563Fig. 2Post-hoc analysis: probability of successful weaning in patients presenting with PaO~2~/FIO~2~ ≤150 versus \>150 (only surviving patients)

Secondary outcome results {#Sec13}
-------------------------

After insertion of pumpless extracorporeal lung assist, a *V*~T~ of 3 ml/kg PBW was achieved in most patients which increased moderately (as spontaneous breathing increased) to day 6 after randomization (Fig. [3](#Fig3){ref-type="fig"}), while in control patients *V*~T~ increased from 6 ml to 8 ml/kg/PBW (*p* \< 0.001 between groups). Minute ventilation was significantly decreased, and the difference between plateau pressure and PEEP (*P*~plat~ − PEEP) was significantly reduced in study patients compared to control.Fig. 3Mean tidal volumes (ml per kg predicted body weight), minute ventilation and difference of plateau pressure and PEEP (*P*~plat~ − PEEP), in the treatment and control groups during the study period

The fractional amount of augmented spontaneous breathing as a percent of total minute ventilation was significantly increased from day 3 in avECCO~2~-R compared to control (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Percent of spontaneous ventilation on minute ventilation and oxygenation (PaO~2~/FIO~2~) in the treatment and control groups during the study period

In line with previous data, extracorporeal CO~2~ removal required higher FIO~2~ which is thought to be due to the lower partial pressure of alveolar oxygen (PAO~2~) secondary to a decreased lung respiratory quotient \[[@CR19]\], and due to a reduction in functional residual capacity with a *V*~T~ of 3 ml/kg compared to 6 ml/kg \[[@CR20]\]. PaCO~2~-values, arterial pH, and mean respiratory rates/min were similar between groups, but mean PEEP levels tended to be elevated in the study group. During the study period, patients with avECCO~2~-R had a modest reduction in MAP without increased demand for continuous norepinephrine infusion.

The cumulative amount of opioid (sufentanil) and benzodiazepine infusion (midazolam) was significantly lower in the study group, but mean RASS-scores were not different between groups during the study period (Fig. 5, ESM).

The number of units of red blood cells transfused was significantly higher in the avECCO~2~-R -group in the period between randomization and day 10 (3.7 ± 2.4 units RBC) compared with control (1.5 ± 1.3, *p* \< 0.05). The incidence of avECCO~2~-R -related adverse events was low (3 patients = 7.5 %): in one patient, transient ischemia of the lower limb was observed, while two patients developed a 'false' aneurysm as a result of arterial cannulation. The overall hospital mortality was low (16.5 %) and we found no significant difference between avECCO~2~-R-group (17.5 %) and control (15.4 %).

Results of the cytokine assessments {#Sec14}
-----------------------------------

TNF-α, IL-6, and IL-8 levels are presented in Table [4](#Tab4){ref-type="table"}. Serum TNF-α levels remained unchanged during the early study period in both groups, while IL-6 levels decreased significantly in the avECCO~2~-R-group, but not in the control group within 24 h after study initiation. IL-8 levels increased in the first few study days in the control group, but not in study patients.Table 4The serum level of tumor necrosis factor (TNF), interleukin 6 (IL-6), and interleukin 8 (IL-8) in treatment and control patients (median values and 25/75 percentiles)TNF (pg/ml)Before begin of the study24 h48 h72 havECCO~2~-R (*n* = 20)19.8 (13.8--23)20 (13.2--23.6)15.3 (13.7--21.4)22.5 (12.8--33.2)Control (*n* = 15)20.5 (14.2--26.8)21 (13.9--48.6)15.9 (13.6--28)15.2 (12.7--25)IL-6 (pg/ml) avECCO~2~-R (*n* = 20)163 (86--419)85 (50--193)^**\$**^53 (20--109)^**\$\$**^60 (35--155)^**\$**^ Control (*n* = 15)97 (84--214)111 (52--171)102 (58--166)64 (18--90)IL-8 (ng/l) avECCO~2~-R (*n* = 20)72 (23--98)65 (30--100)71 (28--94)81 (43--120) Control (*n* = 15)34 (23--49)36 (24--126)45 (29--529)25 (17--191)^**\$**^*p* \< 0.05 in comparison with before^**\$\$**^*p* \< 0.01 in comparison with before

Discussion {#Sec15}
==========

Lung protective ventilation using *V*~T~'s of 6 ml/kg/PBW and limiting *P*~plat~ to 30 cmH~2~O improves outcomes in patients with acute lung injury \[[@CR4]\]. However, the concept that this approach may not be sufficiently lung protective in all patients has been suggested by a post hoc analysis of the ARDSNet data \[[@CR5]\], by animal investigations \[[@CR21]\], human physiological studies \[[@CR3]\], and by a clinical study \[[@CR11]\]. We extended these findings in patients with severe established ARDS by performing a prospective randomized trial using a strategy of very low tidal volume ventilation (3 ml/kg) and an extracorporeal lung assist system providing CO~2~-elimination.

The main findings of our study are: (1) Ventilation with ≈3 ml/kg PBW combined with avECCO~2~-R was safe and feasible, and did not result in physiologically relevant hypercapnia/acidosis. (2) The use of extracorporeal CO~2~-elimination was associated with a significant reduction in analgesic and sedative use, and resulted in an increased ratio of spontaneous breathing compared to control. (3) The serum levels of the pro-inflammatory cytokine IL-6 were significantly reduced in the early study period in patients treated with very low *V*~T~ compared to control patients, and (4) Mechanical ventilation using lower tidal volumes (3 ml/kg) assisted by extracorporeal CO~2~-removal was not associated with a significant reduction of the period of mechanical ventilation within 28 or 60 days or the intensive care and hospital stay, but a post hoc analysis demonstrated that ARDS patients who were more hypoxemic (PaO~2~/FIO~2~ ≤150 at randomization) at baseline and who were treated with the low *V*~T~ strategy had a significantly shorter ventilation period.

The strength of this study is the evaluation of patients with 'established' ARDS: We only accepted patients for randomization who passed a 'stabilization period' (24-h ventilation period with high PEEP) and other measures of optimization and who continued to have persistent impairment of oxygenation (PaO~2~/FIO~2~ ≤200). In a recent analysis \[[@CR13]\] this patient group was identified as having a high mortality compared to patients with PaO~2~/FIO~2~ \>200. However, our study has limitations. Due to a restriction of the enrolment period to 3 years and a 'strict' recruitment protocol we did not reach the pre-specified sample size. Another limitation is the fact that we only enrolled patients with stable hemodynamics, since severe cardiovascular instability was an exclusion criterion for the pumpless circuit. This exclusion criterion might explain the very low mortality rate in the overall study population.

Tidal hyperinflation \[[@CR3], [@CR4], [@CR22]\], and cyclic recruitment/derecruitment \[[@CR23], [@CR24]\] are important mechanisms leading to ventilator-induced lung injury in patients with ARDS, but sufficient clinical data are lacking indicating that a reduction of these phenomena is beneficial. The inhomogeneously injured lung leads to heterogeneous distribution of airway pressure and *V*~T~, resulting in partial hyperinflation, cyclic opening and closing of moderate injured lung regions, and no ventilation in atelectatic regions, making it difficult to chose a single *V*~T~ that completely limits 'global' stress/strain injury \[[@CR25]\]. Since it is not possible to adopt ventilation to the protective 'demands' of different lung regions, we hypothesized that even a small *V*~T~ of 6 ml/kg might aggravate VILI, and therefore we carried out the first reported randomized controlled study using a very low tidal volume lung strategy.

Our data demonstrate the integration of augmented spontaneous breathing in the ventilation management of severe ARDS patients \[[@CR26], [@CR27]\] without a consequent increase in tidal volume or in the demand for sedative agents. We hypothesize that avECCO~2~-R might allow an easy 'switch' from controlled low *V*~T~-ventilation to augmented spontaneous breathing with minimal patient-ventilator asynchrony. Although we did not formally assess ineffective breathing or other signs of asynchrony, we demonstrated that the respiratory rate was not different between the groups, whereas the demand for sedation was significantly lower in the avECCO~2~-R group. A reduction of the hypercapnia likely resulted in decreased respiratory drive as shown by Karagiannidis and coworkers \[[@CR28]\] using neurally adjusted ventilatory assist (NAVA).

In the present study, avECCO~2~-R required higher fractional inspiratory oxygen concentration to maintain adequate oxygenation, while both patient groups were treated with the same high PEEP management. There are two possible mechanisms to explain this finding. The first is a decrease in alveolar ventilation due to the removal of CO~2~ by the extracorporeal circuit \[[@CR19]\], and the second mechanism relates to potential de-recruitment of the lung as demonstrated by Dembinski et al. \[[@CR29]\] in a lung lavage animal model (*V*~T~ 3 ml/kg and avECCO~2~-R). However, in this study the authors used a relatively low PEEP level (5 cmH~2~O), where we used a 'high PEEP strategy'. Such a finding is of clinical relevance when considering extracorporeal CO~2~-elimination as an adjunct measure for lung protective ventilation \[[@CR30]\] with very low *V*~T~ \[[@CR31]\]. A 'safe border' of *V*~T~ to derecruitment is not known.

On the other hand use of very small *V*~T~'s might reduce VILI. Using an experimental model, Frank et al. \[[@CR21]\] demonstrated that a reduction in *V*~T~ from 6 to 3 ml/kg led to a further reduction of epithelial and endothelial injury (extravascular lung water, alveolar epithelial type I cell antigen \[RT 140\]) in acid-injured rat lungs. In line with these experimental findings we found that ventilation with very low *V*~T~ reduced serum levels of the proinflammatory cytokine IL-6 compared with 'normal' protective *V*~T~.

In recent years, techniques of extracorporeal lung support have become easier to use, with smaller devices and greater efficacy. There is evidence that this has led to a reduction in the rate of severe complications \[[@CR32]\]. In the present study only moderate complications attributable to avECCO~2~-R occurred in three patients (7.5 %), and none led to permanent impairment. This complication rate is down from 24 and 12 % \[[@CR10], [@CR15]\], likely related to the use of a screening algorithm, careful evaluation, new material and a modified insertion technique \[[@CR15]\].

In summary, we demonstrate that the use of very low tidal volume (≈3 ml/kg PBW) combined with extracorporeal elimination of carbon dioxide is feasible without major side effects and might be beneficial in the treatment of patients with severe ARDS. The integration of augmented spontaneous breathing might be easier and more comfortable with extracorporeal CO~2~-removal, and a reduced demand for sedative and analgesic medication could be advantageous. Future studies are required to determine whether 'ultraprotective' ventilation will improve survival in patients suffering from severe ARDS.
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